MSB
Director Trades
| Date | Director | Value |
|---|---|---|
| 12/12/24 | E. Rose | $1,500,000 |
| 15/1/25 | E. Rose | $811,096 |
| 27/2/25 | J. Bell | $199,999 |
| 2/3/25 | G. George | $23,474,018 |
| 9/3/25 | G. George | $1,525,055 |
| 20/4/25 | G. George | $817,531 |
Company News
Mesoblast’s Ryoncil becomes first cell therapy approved in the US for acute graft-versus-host disease
Regenerative medicine company Mesoblast (ASX: MSB) has been granted US Food and Drug Administration (FDA) approval for its Ryoncil therapy to treat children with steroid-refractory acute graft-versus-host disease (SR-aGvHD). The off-the-shelf drug derived from bone marrow has become the first mesenchymal stromal cell therapy on the US market to treat the condition, which can occur […]
Mesoblast receives coveted FDA designation for Revascor heart treatment
Cellular medicines developer Mesoblast (ASX: MSB) is celebrating the granting of new US Food and Drug Administration (FDA) approval for its Revascor heart disease treatment. The FDA has granted its highly-sought rare pediatric disease (RPD) designation for Revascor following submission of results from a randomised, controlled trial in children with hypoplastic left heart syndrome (HLHS). […]
TPG Global bids for InvoCare, Xero culls workforce and Myer posts record half sales
Private equity firm TPG Global has taken advantage of beleaguered funeral services company InvoCare’s (ASX: IVC) lacklustre FY2022 results, with a non-binding cash takeover offer valuing it at $12.64 per share. Under the non-binding indicative offer, which was made on Tuesday, TPG is proposing to give InvoCare shareholders $12.65 cash for each share held. This […]
Can these fallen small cap angels regain their wings?
One of the trickiest aspects of investing is deciding whether a fallen angel will ever fly again. If they do regain their wings, the rewards of buying in at distressed levels can be enormous. But as they impress on newcomers in Masterchef safety briefings, trying to catch a falling knife can be highly injurious. As […]
What are the ASX stocks vulnerable to a ‘short squeeze’?
Could the ASX become subject to the same trading shenanigans in the US which put a rocket up the share price of struggling video outlet operator GameStop and then the silver market. It’s certainly food for short … er, thought. This month shares in online travel agent Webjet (ASX: WEB) have climbed around 10% as […]
Mesoblast’s lead drug candidate achieves major regulatory milestone after US FDA vote
Shares in Australian biotech midcap Mesoblast (ASX: MSB) have hit their highest point in more than six years today, following the US Food and Drug Administration’s Oncological Drugs Advisory Committee’s positive vote for remestemcel-L. The FDA voted nine-to-one in favour of data supporting the efficacy of remestemcel-L in children with steroid-refractory acute graft versus host […]
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]
Mesoblast sees strong revenue growth as maintains busy clinical program with upcoming Ryoncil launch
In an interim performance update focusing on the past nine months, dual-listed cellular medicines company Mesoblast (ASX: MSB) reported it had achieved a “strong financial position” and made progress with its lead candidate remestemcel-L, a drug being developed to treat severe cytokine release syndromes. Mesoblast said it saw its revenues increase by 113% to US$31.5 […]
Mesoblast’s remestemcel-L drug could boost COVID-19 survival rates
Mesoblast’s (ASX: MSB) advanced remestemcel-L drug could potentially boost the survival rate of critically ill COVID-19 patients who have developed acute respiratory distress syndrome, with initial results revealing an 83% survival rate for patients treated with the drug compared to 12%. According to Mesoblast, 10 out of 12 COVID-19 ventilator-dependent patients with acute respiratory distress […]
Mesoblast’s remestemcel-L receives FDA IND clearance for treating COVID-19 patients with acute respiratory distress
Regenerative medicine company Mesoblast (ASX: MSB) has received US Food and Drug Administration Investigational New Drug (IND) clearance for its remestemcel-L treatment to be used in COVID-19 patients presenting with acute respiratory distress syndrome. According to Mesoblast chief medical officer Dr Fred Grossman, the FDA IND approval now enables US-based COVID-19 patients with poor prognosis […]